

Adalimumab

[Dosage](#) [Administration advice](#) [Off-label use](#) [Practice points](#) [Products](#)

A–Z drug finder

Drug name				
A	B	C	D	E
F	G	H	I	J
K	L	M	N	O
P	Q	R	S	T
U	V	W	X	Y–Z

Brand name

Adalimumab

TNF-alpha antagonist

For more detailed drug information, see [Adalimumab](#) in the AMH.

Dosage – Adalimumab

Seek paediatric specialist advice relevant to indication (eg rheumatologist, gastroenterologist, dermatologist or ophthalmologist).

Juvenile idiopathic arthritis

Use with [methotrexate](#), or alone if methotrexate not tolerated.

If no response after the initial 12 weeks, consider stopping adalimumab treatment.

Polyarticular

2–18 years

10–30 kg, SC 20 mg once every 2 weeks.

>30 kg, SC 40 mg once every 2 weeks.

Enthesitis-related

6–18 years

10–30 kg, SC 20 mg once every 2 weeks.

>30 kg, SC 40 mg once every 2 weeks.

Refractory non-infectious anterior uveitis

Use with [methotrexate](#).

2–18 years

<30 kg, SC 20 mg once every 2 weeks.

(Alternatively, a loading dose of 40 mg may be given 1 week before the above dose.)

>30 kg, SC 40 mg once every 2 weeks.

(Alternatively, a loading dose of 80 mg may be given 1 week before the above dose.)

Moderate-to-severe Crohn's disease, ulcerative colitis

6–18 years

<40 kg, SC 80 mg on day 0, then 40 mg on day 14, then 20 mg once every 2 weeks starting on day 28. Consider giving the maintenance dose once a week if disease flares or response is poor.

>40 kg, SC 160 mg on day 0 (or 80 mg on each of day 0 and day 1), then 80 mg on day 14, then 40 mg once every 2 weeks starting on day 28. Consider increasing the maintenance dose to 40 mg once a week or 80 mg once every 2 weeks if disease flares or response is poor.

Severe chronic plaque psoriasis

If no response after the initial 16 weeks, consider stopping adalimumab treatment.

4–18 years

<40 kg, SC 20 mg once a week for the first 2 doses, then once every 2 weeks.

>40 kg, SC 40 mg once a week for the first 2 doses, then once every 2 weeks.

Active moderate-to-severe hidradenitis suppurativa

If no response after the initial 12 weeks, consider stopping adalimumab treatment.

12–18 years, SC 80 mg then, starting 1 week after the first dose, 40 mg once every 2 weeks.

Consider increasing the maintenance dose to 40 mg once a week or 80 mg once every 2 weeks if response is poor.

Administration advice

Give SC injection in the front of the thigh or in the abdomen (except area around umbilicus).

For information about parenteral administration, see the [Royal Children's Hospital Paediatric Injectable Guidelines](#).

Off-label use

Product information does not include doses for ulcerative colitis in children.

Practice points

- immunosuppression increases the risk of infection; before starting treatment, consider vaccination requirements and infection risk, see [Immunomodulators](#) in AMH
- antibodies to adalimumab can develop during treatment, which is associated with reduced efficacy; the incidence is:
 - lower when also treated with methotrexate
 - about 10% higher in children with JIA than in adults with rheumatoid arthritis
 - lower in children with Crohn's disease and ulcerative colitis compared to other indications

Products

[Search for Adalimumab on the PBS](#)

inj, 20 mg, 0.2 mL (syringe), 2, *Humira*, PBS-A^{1,2}/PBS-S100³

inj, 20 mg, 0.4 mL (syringe), 2, *Abrilada*^a, *Amgevita*^a, PBS-A¹/PBS-S100³

inj, 40 mg, 0.4 mL (syringe), 2, *Adalicip*^a, *Hadlima*^a, *Humira*, *Yuflyma*^a, PBS-A^{1,2,3,4,5}/PBS-S100³

inj, 40 mg, 0.4 mL, 2, *Adalicip*^{a,b}, *Hadlima*^{a,b}, *Humira*^b, *Yuflyma*^{a,b}, PBS-A^{1,2,3,4,5,6}/PBS-S100³

inj, 40 mg, 0.8 mL (syringe), 2, *Abrilada*^a, *Amgevita*^a, *Hadlima*^a, *Hyrimoz*^a, PBS-A^{1,2,3,4,5}/PBS-S100³

inj, 40 mg, 0.8 mL, 2, *Abrilada*^{a,b}, *Amgevita*^{a,b}, *Hadlima*^{a,b}, *Hyrimoz*^{a,b}, PBS-A^{1,2,3,4,5,6}/PBS-S100³

inj, 80 mg, 0.8 mL (syringe), 1, *Humira*, *Yuflyma*^a, PBS-A^{1,5,6}

inj, 80 mg, 0.8 mL, 1, *Humira*^b, *Yuflyma*^{a,b}, PBS-A^{1,5,6}

¹ Crohn's disease; ulcerative colitis; see PBS

² non-infectious uveitis, see PBS

³ JIA, see PBS

⁴ rheumatoid or psoriatic arthritis; ankylosing spondylitis; see PBS

⁵ severe chronic plaque psoriasis, see PBS

⁶ moderate-severe hidradenitis suppurativa, see PBS

^a biosimilar, see [Prescribing biosimilar products](#) in AMH

^b preloaded injector

[Top of page](#)